After a weak first half, the drug and biotech sector has recovered in the past 2-3 months with large drugmakers like Pfizer, AstraZeneca, Eli Lilly and Novo Nordisk signing drug pricing agreements ...

SANA develops engineered cell therapies for diabetes, autoimmune diseases, and cancer using ex vivo HIP and in vivo fusogen platforms. SC291 is their CD19‑targeted allogeneic CAR-T candidate which ...

Biotech stocks trade on FDA trial phases. Phase 2 data often builds value, cash runway limits dilution, and Quantum BioPharma ...

FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered exceptional ...

AI investment is running hard, even with high interest rates, and that kind of capital hunger often spills into healthcare ...

Biotech stocks have a way of making smart people do dumb things. It starts innocently enough. You read about a "breakthrough" that sounds like it came straight out of science fiction. A tiny company ...

Lixte Biotechnology (ISIN: US53833K1060) develops novel cancer therapies targeting key tumor regulators. North American investors eye its clinical-stage assets amid biotech volatility. Understand the ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

A new framework proposes matching specific financial instruments to three stages of biotechnological development, from early ...